Presentation is loading. Please wait.

Presentation is loading. Please wait.

1 Daniel Keebler DST/NRF Centre of Excellence in Epidemiological Modelling and Analysis (SACEMA) Stellenbosch University, South Africa HIV Modelling Consortium.

Similar presentations


Presentation on theme: "1 Daniel Keebler DST/NRF Centre of Excellence in Epidemiological Modelling and Analysis (SACEMA) Stellenbosch University, South Africa HIV Modelling Consortium."— Presentation transcript:

1 1 Daniel Keebler DST/NRF Centre of Excellence in Epidemiological Modelling and Analysis (SACEMA) Stellenbosch University, South Africa HIV Modelling Consortium How Should HIV Programmes Monitor Adults on ART? A Combined Analysis of Three Mathematical Models

2 Acknowledgements Paul Revill 2, Scott Braithwaite 3, Andrew Phillips 4, Nello Blaser 5, Annick Borquez 6*, Valentina Cambiano 4*, Andrea Ciaranello 7*, Janne Estill 5*, Richard Gray 8*, Andrew Hill 9*, Olivia Keiser 5*, Jason Kessler 3*, Nicolas A. Menzies 10*, Kimberly A. Nucifora 3*, Luisa Salazar Vizcaya 5*, Simon Walker 2*, Alex Welte 1*, Philippa Easterbrook 11, Meg Doherty 11, Gottfried Hirnschall 11 & Timothy Hallett 6 for the HIV Modelling Consortium *Listed in alphabetical order 2 Centre for Health Economics, University of York, York, UK 3 School of Medicine, New York University, New York, US 4 University College London, London, UK 5 Division of International and Environmental Health, Institute of Social and Preventive Medicine (ISPM) University of Bern, Bern, Switzerland 6 Imperial College London, London, UK 7 Massachussetts General Hospital, Boston, MA, US 8 Kirby Institute, University of New South Wales, Sydney, Australia 9 University of Liverpool, Liverpool, UK 10 Centre for Health Decision Science, Harvard University 11 HIV Programme, World Health Organization, Geneva, Switzerland 2

3 The question addressed "How can available resources for HIV treatment and monitoring be allocated among alternative adult patient monitoring strategies to maximize health benefits in a population?" 3

4 The question addressed … considering:  the criteria used (clinical, immunological, virological)  the frequency of monitoring (6, 12, 36 months)  the decision rules applied (when to switch to 2 nd -line) Examining the:  Benefits (Life-years saved, infections averted, DALYS averted)  Costs (USD $ over short and long-terms) 4

5  Previous modelling work has been done on this question.  Compare alternative potential monitoring strategies “head-to- head” in each model, with standardized cost inputs.  Focus on costs in three settings: South Africa, Zambia and Malawi Approach: model comparison 5

6 Models 1. Phillips AN, Pillay D, Miners AH, Bennett DE, Gilks CF, Lundgren JD. Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model. Lancet. 2008; 371(9622): Epub 2008/04/ Braithwaite RS, Nucifora KA, Yiannoutsos CT, Musick B, Kimaiyo S, Diero L, et al. Alternative antiretroviral monitoring strategies for HIV-infected patients in east Africa: opportunities to save more lives? Journal of the International AIDS Society. 2011; 14:38. Epub 2011/08/ Estill J, Aubriere C, Egger M, Johnson L, Wood R, Garone D et al. Viral load monitoring of antiretroviral therapy, cohort viral load and HIV transmission in Southern Africa: a mathematical modelling analysis. AIDS. 2012; 26(11): Epub 2012/03/17. 6 ModelGroupStructureType Time horizon Patient benefit TransmissionAdherenceResistance HIV Synthesis 1 UCL Individual based Stochastic15 yearsYES Braithwaite 2 New York University Cohort model, Monte Carlo progression StochasticLifetimeYESNOYES Estill 3 University of Bern Cohort modelStochastic 5 yearsYESNO

7 Strategies investigated AbbreviationScenario NMNo switching or monitoring CM, S4Switch on new stage 4 event CM, S3/4Switch on new stage 3 or 4 event CD4<100/S4Switch if CD4 <100 or new stage 4 CD4-CACurrently widely-used CD4 monitoring algorithm CD4/TGVLSwitch if CD4 a) falls >50% from peak on treatment, b) falls below baseline, with confirmation of viral load >1,000 copies. CD4/TGVL+Switch if CD4 a) falls >50% from peak on treatment, b) falls below baseline, with confirmatory VL >1,000, or new Stage 4, PLUS routine 12 monthly VL at 1,000 (CD4/VL mixed scenario) VL3636 monthly VL; switch if VL>1000 VL1212 monthly VL; switch if VL>1000 VL66 monthly VL; switch if VL>1000 VL6/VL>1K6 monthly VL; switch if VL>10000 VL6/VL>5K6 monthly VL; switch if VL>5000 VL6/VL>5006 monthly VL; switch if VL>500 7

8 Results 8

9 HIV Synthesis: Zambia 9 Range of additional benefits modest Six monthly VL greatest impact. Cost per DALY averted high Clear pathway of prioritisation

10 Cost-Effectiveness Frontier Plots for Zambia (Cost per DALY Averted, 2012 USD) 10 (a) Estill model; (b) Braithwaite et al. model; (c) HIV Synthesis model. Unfavoured (i.e. dominated/extendedly dominated; see Methods) strategies are shown in light grey while most efficient strategies are shown in black and their code is highlighted in bold. The frontier line that represents a most efficient pathway of spending as resources increase is shown in red together with the ICERs, i.e. the incremental cost per DALY averted of moving from one strategy to the next along the frontier.

11 Opportunity Costs 11 If ART coverage targets not met, resources allocated to increasing ART coverage would generate much greater benefits than if allocated to better patient monitoring. Costs and benefits (DALYS averted) of alternative uses of resources (Braithwaite model). Results given are per 1 million HIV-infected persons with both benefits and costs discounted at 3%.

12 Opportunity Costs & Initiation Thresholds 12 Costs per patient lifetime and DALYs averted from alternative uses of resources (Braithwaite model).

13 Reduced 2 nd -Line, Test Costs 13

14 14

15 15 Includes net effect of prevention of unneeded switch and earlier switching in failing patients

16 16 NB: Estill et al. not included owing to model structure

17 Interpretation Not all models could run all scenarios, complicating comparisons (e.g. VL6/500) Bulk of model scenarios more sensitive to test costs than to 2 nd -line costs in sensitivity analyses But proportion of total costs taken up by tests & 2 nd -line, and life-years on 2 nd -line, varied between models Virological failure may also impact on results: if overlap is higher, then virological monitoring may convey less useful information in targeted VL scenarios TGVL performed well in Braithwaite; not as well in Phillips Life-years as proxy for predictive value of CD4  VL failure 17

18 Conclusions: Modelling Results 18

19 Conclusions: Modelling Results (1) Regular viral load (every 6-12 months) provides the most benefits both in reducing patient morbidity and mortality and in reducing HIV transmission in the population… … but is the most expensive strategy for monitoring patients. Infrequent viral load monitoring (every 36 months) or conditional viral load measurement (for confirmation of immunologic failure suggesting a need for second line drugs) would have an intermediate cost but may maximise health benefits for that budget. However, if infrequent/conditional viral load monitoring would lead to machines being used at less the full capacity then these alternatives are less likely to be cost-effective. 19

20 Conclusions: Modelling Results (2) The question is not whether viral load provides greater benefit to individual patients than CD4 or clinical monitoring. The question is whether, given available resources, the opportunity costs in morbidity and mortality of forgoing the use of these resources for other efforts is acceptable. In particular, it is expected that resources would produce greater health benefits if they were committed to increasing the coverage of ART to those in need. Equity should also be a concern: lower-cost but less-effective monitoring strategies may reach a larger number of people than high-cost, more-effective strategies. 20

21 Conclusions: Linking Modelling and Operational Research 21

22 Linking Modelling and Operational Research While we expect the qualitative distribution of results to remain similar, when placed into real-world contexts, precise results given here will change If I devote resources to patient monitoring, what benefits will it yield for program performance in my particular context? The answer depends on… 22

23 Linking Modelling and Operational Research Delays in getting results to lab, back from lab, and to the patient Staff time & capacity for test processing & interpretation (can they do VL or CD4 better?) Capacity for test coverage: centralization vs. de- centralization, lower-cost tests reaching more people Role of monitoring in adherence interventions Program-specific ART coverage and feasible targets for scale-up Willingness-to-pay per DALY averted (level of resources) And more… 23

24 Integration of operational research and modelling is key to assessing program-specific impacts, within a framework of opportunity costs For interpreting and for generating models Development of flexible modelling tools/user-friendly platforms that can incorporate all of the above, and be deployed to programs for their own use in planning, should be investigated 24 Linking Modelling and Operational Research

25 Modelling allows for the examination of strategies’ costs and health impacts over a longer timeframe than trials may allow, and without needing to withhold health interventions for the purpose of comparison Modelling can provide a clear picture of which costs within a given intervention carry the greatest impact Useful for advocates as well as program staff/operational researchers Models can inform programming and operational research, but models must themselves be informed by this: What factors impact how technologies work in the real world? How can these be incorporated into models? Interpreting and building models requires strong linkage between modellers, operational researchers, implementers and advocates 25


Download ppt "1 Daniel Keebler DST/NRF Centre of Excellence in Epidemiological Modelling and Analysis (SACEMA) Stellenbosch University, South Africa HIV Modelling Consortium."

Similar presentations


Ads by Google